AUTHOR=Chi Meng , Jie Yamin , Li Ying , Wang Duo , Li Man , Li Dan , E Mingyan , Li Yongwu , Liu Na , Gu Anxin , Rong Guanghua 

TITLE=Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1189245

DOI=10.3389/fphar.2023.1189245

ISSN=1663-9812

ABSTRACT=<p><bold>Background and aims:</bold> The outcomes of current treatment for non-small cell lung cancer (NSCLC) are unsatisfactory and development of new and more efficacious therapeutic strategies are required. The Notch pathway, which is necessary for cell survival to avert apoptosis, induces the resistance of cancer cells to antitumour drugs. Notch pathway activation is controlled by the cleavage of Notch proteins/receptors mediated by A disintegrin and metalloproteinase 17 (ADAM17); therefore, ADAM17 is a reliable intervention target for anti-tumour therapy to overcome the drug resistance of cancer cells. This work aims to develop and elucidate the activation of Compound <bold>2b</bold>, a novel-structured small-molecule inhibitor of ADAM17, which was designed and developed and its therapeutic efficacy in NSCLC was assessed via multi-assays.</p><p><bold>Methods and results:</bold> A lead compound for a potential inhibitor of ADAM17 was explored via pharmacophore modelling, molecular docking, and biochemical screening. It was augmented by substituting two important chemical groups [R1 and R2 of the quinoxaline-2,3-diamine (its chemical skeleton)]; subsequently, serial homologs of the lead compound were used to obtain anoptimized compound (<bold>2b</bold>) with high inhibitory activity compared with leading compound against ADAM17 to inhibit the cleavage of Notch proteins and the accumulation of the Notch intracellular domain in the nuclei of NSCLC cells. The inhibitory activity of compound <bold>2b</bold> was demonstrated by quantitative polymerase chain reaction and Western blotting. The specificity of compound <bold>2b</bold> on ADAM17 was confirmed via point-mutation. Compound <bold>2b</bold> enhanced the activation of antitumor drugs on NSCLC cells, in cell lines and nude mice models, by targeting the ADAM17/Notch pathway.</p><p><bold>Conclusion:</bold> Compound <bold>2b</bold> may be a promising strategy for NSCLC treatment.</p>